Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Masked, Uncontrolled , Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naive Participants With Neovascular Age-Related Macular Degeneration (AMD)

Next Previous
Trial Profile

A Randomized, Double Masked, Uncontrolled , Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naive Participants With Neovascular Age-Related Macular Degeneration (AMD)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PAN 90806 (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors PanOptica

    • Most Recent Events

    • 10 Oct 2019 According to a PanOptica media release, topline results from this study were presented at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology annual meeting (OIS@AAO, in San Francisco).
    • 10 Oct 2019 Topline results presented in a PanOptica media release.
    • 07 Oct 2019 According to a PanOptica media release, the company will present topline data from this study at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO, 10th Oct 2019, in San Francisco).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top